Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Free Cash Flow (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Free Cash Flow for 7 consecutive years, with -$17.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow changed 0.21% to -$17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$60.4 million, a 2319.03% decrease, with the full-year FY2025 number at -$60.4 million, down 2319.03% from a year prior.
  • Free Cash Flow was -$17.0 million for Q4 2025 at Fulcrum Therapeutics, down from -$14.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $58.9 million in Q2 2024 to a low of -$28.7 million in Q2 2022.
  • A 5-year average of -$16.5 million and a median of -$20.2 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 331.2% in 2021, then soared 379.56% in 2024.
  • Fulcrum Therapeutics' Free Cash Flow stood at -$20.7 million in 2021, then grew by 4.83% to -$19.7 million in 2022, then decreased by 17.93% to -$23.2 million in 2023, then grew by 26.87% to -$17.0 million in 2024, then rose by 0.21% to -$17.0 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Free Cash Flow are -$17.0 million (Q4 2025), -$14.3 million (Q3 2025), and -$13.9 million (Q2 2025).